Inventiva S.A. American Depository Shares (IVA)

FairStock Score: 20/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable earnings, low debt, and a margin of safety. Inventiva does not fit that mold. It is a clinical-stage biotech with Lanifibranor in Phase 3 for MASH and Odiparcil behind it. At the 2026-10-13 close of $2.87, the market cap is $1.1B. FairStock's P/E is -4.70, ROE is -989.05%, and ROCE is -42.69%, so capital is being consumed, not compounded. Debt-to-equity of 2.35 and an Altman Z-Score of 1.16 point to balance-sheet stress, while a Piotroski F-Score of 2/9 confirms weak fundamentals. There is no P/B and no Lynch category because FairStock counts only 0 year(s) of filed annual results and needs 3, so there is little operating history to judge. Beta of 0.92 is mild, but irrelevant if the science is binary. A moat? None yet; only clinical data and intellectual property can create one. Growth is not revenue-driven; it depends on trial outcomes and financing. The $2.87 price sits at the 52-week low, and the FairStock Score is 20/100, reflecting deep pessimism. If Phase 3 succeeds, the value could change dramatically; if it fails or is delayed, dilution and solvency risk are real. Graham would demand asset protection or proven earnings. Buffett would demand a durable franchise. Here I see a speculative clinical option with an 87-employee team, not a compounding machine. I would need clinical and financial proof before calling it a value investment.

In plain English: Inventiva is a small healthcare company testing experimental medicines, mainly an oral drug for a serious liver disease called MASH. It has no proven product profits yet, loses money, and carries a lot of debt, so the business looks financially weak. At $2.87 on 2026-10-13, the market is pricing in hope for clinical trial results rather than current earnings, so the shares look speculative rather than plainly cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer